{
    "id": 15107,
    "fullName": "MCL1 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MCL1 amp indicates an increased number of copies of the MCL1 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4170,
        "geneSymbol": "MCL1",
        "terms": [
            "MCL1",
            "bcl2-L-3",
            "BCL2L3",
            "EAT",
            "Mcl-1",
            "MCL1-ES",
            "mcl1/EAT",
            "MCL1L",
            "MCL1S",
            "TM"
        ]
    },
    "variant": "amp",
    "createDate": "12/11/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3744,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, solid tumor cell lines with MCL1 amplification demonstrated increased sensitivity to treatment with Dinaciclib in culture (PMID: 25289887).",
            "molecularProfile": {
                "id": 15366,
                "profileName": "MCL1 amp"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4094,
                    "pubMedId": 25289887,
                    "title": "MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25289887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11545,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with MCL1 amplification and a NFE2L2 missense mutation, experienced disease progression after initial response to Zykadia (ceritinib) treatment for 7 months, then received Alecensa (alectinib) and remained on treatment for at least 45 months (PMID: 28476735).",
            "molecularProfile": {
                "id": 28132,
                "profileName": "EML4 - ALK MCL1 amp NFE2L2 mut"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11546,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with MCL1 amplification and a NFE2L2 missense mutation, experienced disease progression after initial response to Zykadia (ceritinib) treatment for 7 months, then received Alecensa (alectinib) and remained on treatment for at least 45 months (PMID: 28476735).",
            "molecularProfile": {
                "id": 28132,
                "profileName": "EML4 - ALK MCL1 amp NFE2L2 mut"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15366,
            "profileName": "MCL1 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7215,
                    "name": "Dinaciclib",
                    "profileName": "MCL1 amp"
                },
                {
                    "id": 7214,
                    "name": "BCL2 Family Inhibitor",
                    "profileName": "MCL1 amp"
                },
                {
                    "id": 7213,
                    "name": "MCL1 Inhibitor",
                    "profileName": "MCL1 amp"
                }
            ]
        },
        {
            "id": 28132,
            "profileName": "EML4 - ALK MCL1 amp NFE2L2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}